Attached files
| file | filename |
|---|---|
| EX-21.1 - EX-21.1 - Ikena Oncology, Inc. | d197729dex211.htm |
| EX-10.10 - EX-10.10 - Ikena Oncology, Inc. | d197729dex1010.htm |
| EX-10.9 - EX-10.9 - Ikena Oncology, Inc. | d197729dex109.htm |
| EX-10.8 - EX-10.8 - Ikena Oncology, Inc. | d197729dex108.htm |
| EX-10.7 - EX-10.7 - Ikena Oncology, Inc. | d197729dex107.htm |
| EX-10.1 - EX-10.1 - Ikena Oncology, Inc. | d197729dex101.htm |
| EX-4.2 - EX-4.2 - Ikena Oncology, Inc. | d197729dex42.htm |
| EX-3.3 - EX-3.3 - Ikena Oncology, Inc. | d197729dex33.htm |
| EX-3.1 - EX-3.1 - Ikena Oncology, Inc. | d197729dex31.htm |
| EX-2.2 - EX-2.2 - Ikena Oncology, Inc. | d197729dex22.htm |
| EX-2.1 - EX-2.1 - Ikena Oncology, Inc. | d197729dex21.htm |
| S-1 - S-1 - Ikena Oncology, Inc. | d197729ds1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 5, 2021, in the Registration Statement (Form S-1) and related Prospectus of Ikena Oncology, Inc. dated March 5, 2021.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 5, 2021